期刊文献+

白藜芦醇对小鼠营养性肥胖伴生殖功能损害的作用 被引量:1

Role of resveratrol in diet-induced obesity and reproductive insufficiency in mice
原文传递
导出
摘要 目的探讨白藜芦醇对肥胖性不育的防治作用。方法36只雌性昆明小鼠按随机区组法分为3组(对照组、高脂组和干预组),每组12只,分别喂以正常饮食、高脂饮食和高脂饮食加白藜芦醇。分别在4周、8周和12周时监测动物体重、空腹血糖和糖耐量情况。喂养12周后检测小鼠空腹胰岛素、血清雌二醇、黄体生成素、睾酮水平,以阴道脱落细胞判断小鼠动情周期,以雌、雄个体3:1的比例进行交配,观察小鼠生育能力。结果喂养12周后高脂组和干预组小鼠体重[(61.52±6.92),(63.06±5.80)g]都明显高于对照组[(47.76±5.02)g],差异具有统计学意义(P〈0.05);而干预组体重相对于高脂组差异没有统计学意义(P〉0.05)。高脂组空腹血糖[(6.98±0.33)mmol/L]和空腹胰岛素[(38.02±7.21)μIU/L]明显高于对照组[(5.30±0.36)mmol/L,(30.29±5.58)μlU/L],差异均具有统计学意义(P〈0.05);干预组空腹血糖[(5.45±0.67)mmol/L]和空腹胰岛素[(30.21±4.60)μIU/L]与高脂组相比明显下降,且差异均具有统计学意义(P〈0.05)。性激素分析显示高脂组雌二醇[(5.67±0.98)ng/L]与黄体生成素l(0.346±0.025)IU/L]较对照组[(3.007±0.721)ng/L,(0.202±0.041)IU/L]明显升高(P〈0.05);干预组雌二醇[(2.115±0.353)ng/L]和黄体生成素[(0.245±0.041)IU/L]与高脂组相比明显下降,差异均具有统计学意义(P〈0.05)。睾酮含量各组之间没有统计学差异。高脂饮食还导致动情周期紊乱甚至消失,卵巢组织学显示高脂饮食导致闭锁卵泡数量明显增加。结论高脂饮食能够诱导雌性小鼠肥胖、代谢综合征与生殖功能榻害.白藜芦醇对此能起到一定缓解作用。 Objective To investigate the role of reselweratrol in rescue of obesity-induced infertil- ity. Methods According to randomized block design, thirty-six female Kunming mice were randomly divided into three groups (control group, high-fat group and treatment group) , and twelve in each group. Three groups were fed with a standard rodent chow, a high-fat diet, or a high-fat diet plus resveratrol, respectively. Body weight, fasting blood glucose, and an intraperitoneal glucose tolerance test were determined at 4th, 8th, and 12th week. At the 12th week,fasting insulin, estrogen,lnteinizing hormone, and testosterone were measured. The number of vaginal exfoliated cells was counted to determine the estrous cycle of mice. Three female mice were mated with a male in order to assess mice fertility. Results After 12 weeks of feeding, the body weights of high-fat group [ (61.52 ± 6.92 ) g ] and treatment group [ ( 63.06 ± 5.80 ) g ] were significantly higher than that in control group [ ( 47.76 ± 5.02 ) g], and had statistical difference ( P 〈 0.05 ), while the body weights between high-fat group and treatment group had no differences ( P 〉 0. 05 ). Fasting blood glucose [ (6.98 ±0.33) mmol/L] and fasting insulin [ (38.02 ±7.21 ) μIU/L]in high-fat group were significandyhigher than those of control group [ (5.30 ±0.36) mmol/L, (30.29 ±5.58) μIU/L,P 〈0.05 ]. Compared with high-fat group, fasting blood glucose [ ( 5.45 ± 0.67 ) mmol/L ] and fasting insulin [ ( 30.21 ± 4.60 ) μIU/L ] of treatment group were decreased significantly (P 〈 0.05 ). Estrogen [ (5.67 ± O. 98 ) ng/L ] and luteinizing hormone [ ( 0. 346 ± 0. 025) IU/L ] of high-fat group were significantly increased than those of control group [ (3. 007 ± 0. 721 ) ng/L, (0. 202 ± 0. 041 ) IU/L, P 〈 0.05 ]. Estrogen [ (2.115 ± 0. 353 ) ng/L] and luteinizing hormone [ (0.245 ± 0. 041 ) IU/L] in treatment group were decreased significantly compared with high-fat group ( P 〈 0.05 ). Testosterone levels among the groups had no significant differ- ences. The high-fat diet also caused a disordered or even an absence of estrous cycle. Ovarian histology showed a marked increase in the number of atretic follicles in high-fat group. Conclusions High-fat diet could induce obesity, signs of metabolic syndrome, and partial reproductive impairment in female Kuming mice. Also, reseveratrol may have beneficial effects in preventing obesity-induced infertility.
出处 《国际内分泌代谢杂志》 北大核心 2013年第3期155-157,162,F0003,共5页 International Journal of Endocrinology and Metabolism
基金 国家重大研究计划项目“973”计划(2010CB945001)
关键词 白藜芦醇 肥胖 代谢综合征 不育 多囊卵巢综合征 Resveratrol Obesity Metabolic syndrome Infertility Polycystic ovary syndrome
  • 相关文献

参考文献12

  • 1张萍,李圣贤,刘伟.11β-羟类固醇脱氢酶1与胰岛素抵抗和多囊卵巢综合征[J].国际内分泌代谢杂志,2012,32(2):103-106. 被引量:3
  • 2Lagouge M, Argmann C, Gerhart Z, et al. Resveratrol improves mi- tochondrial function and protects against metabolic disease by ac- tivating SIRTI and PGC-I alpha. Ce11,2006,127:1109-1122.
  • 3Baur JA,Pearson K J, Price NL,et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature, 2006,444: 337-342.
  • 4Marcondes FK, Bianchi FJ, Tanno AP. Determination of the es- trous cycle phases of rats: some helpful considerations. Braz J Bio1,2002,62:609-514.
  • 5Sheehan MT. Polycystic ovarian syndrome:diagnosis and manage- ment. Clin Med Res ,2004,2 : 13-27.
  • 6Brassard M, AinMelk Y, Baillargeon JP. Basic infertility including polycystic ovary syndrome. Med Clin North Am,2008,92 : 1163- 1192 ,xi.
  • 7Pacholec M, Bleasdale JE, Chrunyk B, et al. SRT1720, SRT2183,SRTI460, and resveratrol are not direct activators of SIRTI. J Biol Chem, 2010,285 : 8340 -8351.
  • 8Henry LA,Witt DM. Resveratrol:phytoestrogen etteets on repro- ductive physiology and behavior in temale rats. Horm Behav 2002,41:220-228.
  • 9Bowers JL, Tyulmenkov VV, Jernigan SC, et al. Resveratrol acts as a mixed agonist/antagonist for estrogen reeeptors alpha and beta. Endocrinology, 2000,141 : 3657-3667.
  • 10Doi SA,A1-Zaid M,Towers PA, et al. Irregular cycles and steroid hormones in polycystie ovary syndrome. Hum Reprod,2005,20: 2402-2408.

二级参考文献17

  • 1Restuccia DF, Hynx D, Hemmings BA. Loss of PKBI/Akt2 pre- disposes mice to ovarian cyst formation and increases the severity of polycystic ovary formation in vivo. Dis Model Mech, 2012, [ Epub ahead of print].
  • 2Knops NB, Monnens LA, Lenders JW. Apparent mineralocorticoid excess : time of manifestation and complications despite treatment. Pediatrics,20! 1,127 : e1610-e1614.
  • 3Svendsen PF, Madsbad S, Nilas L, et al. Expression of 1 l beta- hydroxysteroid dehydrogenase 1 and 2 in subcutaneous adipose tissue of lean and obese women with and without polycystic ovary syndrome. Int J Obe (Lond) ,2009,33 : 1249-1256.
  • 4Holt HB,Wild SH, Postle AD, et al. Cortisol clearance and associ- ations with insulin sensitivity, body fat and fatty liver in middle- aged men. Diabetologia,2007,50 : 1024-1032.
  • 5Wake D J, Homer NZ, Andrew R, et al. Acute in vivo regulation of l lbeta-hydroxysteroid dehydrogenase type 1 activity by insulin and intralipid infusions in humans. J Clin Endocrinol Metab, 2006,91:4682-4688.
  • 6Nuotio-Antar AM, Hachey DL, Hasty AH. Carbenoxolone treat- ment attenuates symptoms of metabolic syndrome and atherogene- sis in obese, hyperlipidemic mice. Am J Physiol Endocrinol Metab, 2007,293 : E1517-E 1528.
  • 7Rosenstock J, Banarer S, Fonseca VA, et al. The 11-beta-hydrox- ysteroid dehydrogenase type 1 inhibitor INCB13739 improves hy- perglycemia in patients with type 2 diabetes inadequately con- trolled by metformin monotherapy. Diabetes Care ,2010,33 : 1516- 1522.
  • 8Li X, Lindquist S, Chen R, et al. Depot-specific messenger RNA expression of 11 beta-hydroxysteroid dehydrogenase type 1 and leptin in adipose tissue of children and adults. Int J Obes (Lond) ,2007,31 : 820-828.
  • 9VeiUeux A, Rheaume C, Daris M, et al. Omental adipose tissue type I 11-beta-hydroxysteroid dehydrogenase oxoreductase activi- ty, body fat distribution, and metabolic alterations in women. J Clin Endocrinol Metab,2009 ,94 :3550-3557.
  • 10Mlinar B, Marc J, Jensterle M, et al. Expression of 1113-hydroxys- teroid dehydrogenase type 1 in visceral and subcutaneous adipose tissues of patients witb polycystie ovary syndrome is associated with adiposity. J Steroid Bioehem Mol Bio1,2011,123 : 127-132.

共引文献2

同被引文献32

引证文献1

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部